EA201390488A1 - Новые агонисты gpr 119 - Google Patents

Новые агонисты gpr 119

Info

Publication number
EA201390488A1
EA201390488A1 EA201390488A EA201390488A EA201390488A1 EA 201390488 A1 EA201390488 A1 EA 201390488A1 EA 201390488 A EA201390488 A EA 201390488A EA 201390488 A EA201390488 A EA 201390488A EA 201390488 A1 EA201390488 A1 EA 201390488A1
Authority
EA
Eurasian Patent Office
Prior art keywords
agonists
gpr
new
preparation
new gpr
Prior art date
Application number
EA201390488A
Other languages
English (en)
Other versions
EA022501B1 (ru
Inventor
Харикишоре Пингали
Пандуранг Заваре
Original Assignee
Кадила Хелзкэр Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кадила Хелзкэр Лимитед filed Critical Кадила Хелзкэр Лимитед
Publication of EA201390488A1 publication Critical patent/EA201390488A1/ru
Publication of EA022501B1 publication Critical patent/EA022501B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms

Abstract

Настоящее изобретение относится к новым агонистам GPR 119 общей формулы (I), их таутомерным формам, их стереоизомерам, их фармацевтически приемлемым солям, содержащим их фармацевтическим композициям, способам их получения, применению этих соединений в медицине и промежуточным соединениям, включенным в их получение.
EA201390488A 2010-10-08 2011-10-05 Агонисты gpr 119 EA022501B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2803MU2010 2010-10-08
PCT/IN2011/000694 WO2012046249A1 (en) 2010-10-08 2011-10-05 Novel gpr 119 agonists

Publications (2)

Publication Number Publication Date
EA201390488A1 true EA201390488A1 (ru) 2013-08-30
EA022501B1 EA022501B1 (ru) 2016-01-29

Family

ID=45464048

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390488A EA022501B1 (ru) 2010-10-08 2011-10-05 Агонисты gpr 119

Country Status (18)

Country Link
US (1) US8785463B2 (ru)
EP (1) EP2625177B1 (ru)
JP (1) JP5814377B2 (ru)
KR (1) KR101563793B1 (ru)
AP (1) AP2013006812A0 (ru)
AR (1) AR083377A1 (ru)
AU (1) AU2011311183B2 (ru)
BR (1) BR112013007904A2 (ru)
DK (1) DK2625177T3 (ru)
EA (1) EA022501B1 (ru)
ES (1) ES2551183T3 (ru)
HK (1) HK1185875A1 (ru)
MX (1) MX2013003736A (ru)
NZ (1) NZ608708A (ru)
PL (1) PL2625177T3 (ru)
SG (1) SG188547A1 (ru)
WO (1) WO2012046249A1 (ru)
ZA (1) ZA201302249B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031618B1 (ru) 2011-06-09 2019-01-31 Ризен Фармасьютикалз Са Соединения-модуляторы gpr-119
EP2872127A1 (en) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ，インク． Ａｍｐｋアクチベーター
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
US8207147B2 (en) 2003-12-24 2012-06-26 Prosidion Limited Heterocyclic derivatives as GPCR receptor agonists
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
NZ564759A (en) 2005-06-30 2011-08-26 Prosidion Ltd GPCR agonists
EP1907384A2 (en) 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
AU2006264651A1 (en) 2005-06-30 2007-01-11 Prosidion Limited G-protein coupled receptor agonists
US20090149508A1 (en) 2005-07-27 2009-06-11 Sandoz Ag Process for the preparation of substituted phenyl ether compounds
CN101263135A (zh) * 2005-09-16 2008-09-10 艾尼纳制药公司 代谢调节剂和代谢相关病症的治疗
US20090221639A1 (en) 2006-04-06 2009-09-03 Lisa Sarah Bertram Heterocyclic GPCR Agonists
GB0607196D0 (en) 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
AU2007334519A1 (en) 2006-12-14 2008-06-26 Merck Sharp & Dohme Corp. Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
AU2008276057B2 (en) 2007-07-17 2013-01-31 Bristol-Myers Squibb Company Method for modulating GPR119 G protein-coupled receptor and selected compounds
WO2009046416A1 (en) * 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
WO2009051119A1 (ja) 2007-10-16 2009-04-23 Daiichi Sankyo Company, Limited ピリミジルインドリン化合物
WO2009106561A1 (en) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Pyrazine compounds for treating gpr119 related disorders
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
WO2009150144A1 (en) 2008-06-10 2009-12-17 Inovacia Ab New gpr119modulators
KR101345941B1 (ko) 2008-07-11 2013-12-30 아이알엠 엘엘씨 Ｇｐｒ119 활성의 조절제로서의 4-페녹시메틸피페리딘
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010075271A1 (en) * 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
EP2379542B1 (en) 2008-12-24 2013-02-13 Cadila Healthcare Limited Novel oxime derivatives

Also Published As

Publication number Publication date
JP2013538870A (ja) 2013-10-17
AR083377A1 (es) 2013-02-21
AU2011311183A1 (en) 2013-04-04
WO2012046249A1 (en) 2012-04-12
BR112013007904A2 (pt) 2019-09-24
US8785463B2 (en) 2014-07-22
MX2013003736A (es) 2013-05-09
EA022501B1 (ru) 2016-01-29
JP5814377B2 (ja) 2015-11-17
EP2625177B1 (en) 2015-07-29
PL2625177T3 (pl) 2015-12-31
DK2625177T3 (en) 2015-10-12
KR101563793B1 (ko) 2015-10-27
EP2625177A1 (en) 2013-08-14
AP2013006812A0 (en) 2013-04-30
KR20130064801A (ko) 2013-06-18
US20130252980A1 (en) 2013-09-26
HK1185875A1 (en) 2014-02-28
AU2011311183B2 (en) 2014-09-25
NZ608708A (en) 2015-05-29
ES2551183T3 (es) 2015-11-16
SG188547A1 (en) 2013-04-30
ZA201302249B (en) 2013-12-23

Similar Documents

Publication Publication Date Title
JO3781B1 (ar) مشتقات الكينولون
PH12016500885A1 (en) Novel heterocyclic compounds
EA201270492A1 (ru) Соединения для лечения дислипидемии и связанных с ней заболеваний
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
IN2014MN02106A (ru)
EA201600366A1 (ru) Производные бензимидазол-пролина
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
EA201490357A1 (ru) Индазолы
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
EA201071329A1 (ru) Диамидные производные адамантана и их применение
EA201200918A1 (ru) Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
EA201390008A1 (ru) Новые ариламидные производные, обладающие антиандрогенными свойствами
EA201600434A1 (ru) Применение производных бензимидазолпролина
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
PH12014501943A1 (en) Novel compounds for the treatment of dyslipidemia and related diseases
EA201291014A1 (ru) Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция
EA201490573A1 (ru) Соединение бензотиазолона
EA201391124A1 (ru) Новые бензодиоксолпиперазиновые соединения
EA201300389A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU